Gan & Lee Pharmaceuticals Co Ltd

Gan & Lee Pharmaceuticals Co Ltd

603087 · SHG · Healthcare / Medical Instruments & Supplies

67.31CNY-1.34 (-1.95%)

Price History

Full chart

Market Stats

Previous Close68.65
Open68.65
Day Range67.03 – 68.99
52-Week Range51.02 – 79.99
Volume4.97M
Market Cap46.24B
P/E (TTM)39.90
Forward P/E0.00
EPS1.94
Dividend Yield1.29%
Beta0.27
50-Day Avg70.19
200-Day Avg64.61

About

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Wei Chen
  • Employees5.31K
  • HeadquartersNo. 8, Nanfeng West 1st Street, Beijing, China, 101109, China
  • Websitehttps://www.ganlee.com

Leadership

  • Mr. Wei ChenChairman & GM · b. 1980
  • Mr. Weiqiang SongDeputy GM & Director · b. 1982
  • Mr. Kai DuDeputy GM & Director · b. 1977
  • Ms. Rong ZouDeputy GM & Secretary · b. 1983
  • Ms. Zifei YuanDeputy General Manager · b. 1989
  • Mr. Zhi LiDeputy General Manager · b. 1993
  • Mr. Qianming Wang Ph.D.CFO & Deputy GM
  • Li ZhouHead of Accounting
  • Ms. Yajuan FengHead of Administrative Department · b. 1992
  • Dr. Ting JiaChief Medical Officer

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue692.64M926.60M1.22B1.77B2.37B2.39B2.90B3.36B3.61B1.71B2.61B3.05B4.05B
Growth (%)-+33.78%+31.64%+45.23%+33.82%+0.71%+21.26%+16.12%+7.44%-52.60%+52.31%+16.77%+33.06%
Cost of Revenue67.41M83.63M109.50M166.37M206.63M187.07M237.98M309.82M399.90M443.93M724.70M777.15M978.95M
Gross Profit625.23M842.97M1.11B1.61B2.16B2.20B2.66B3.05B3.21B1.27B1.88B2.27B3.07B
Gross Margin90.27%90.97%91.02%90.61%91.28%92.16%91.78%90.78%88.93%74.07%72.21%74.48%75.84%
Operating Expense391.35M495.71M588.19M705.13M894.21M1.09B1.26B1.60B1.51B1.84B1.57B1.64B2.28B
Operating Income233.88M347.25M522.12M900.00M1.27B1.11B1.40B1.45B1.70B-568.87M315.29M631.54M793.63M
Operating Margin33.77%37.48%42.80%50.80%53.56%46.67%48.29%43.22%47.03%-33.22%12.09%20.74%19.59%
EBITDA233.91M341.99M521.66M888.21M1.30B1.18B1.44B1.57B1.57B-479.87M400.79M545.57M1.53B
EBITDA Margin33.77%36.91%42.77%50.14%54.81%49.33%49.91%46.83%43.49%-28.03%15.37%17.91%37.84%
Net Income204.73M305.22M447.42M769.63M1.08B933.97M1.17B1.23B1.45B-439.52M340.07M614.66M1.14B
Net Income Margin29.56%32.94%36.68%43.45%45.56%39.12%40.32%36.61%40.22%-25.67%13.04%20.18%28.22%
R&D31.40M39.75M50.08M95.88M137.57M143.49M235.56M419.99M474.59M562.47M501.02M541.05M646.97M
R&D as % of Total Revenue4.53%4.29%4.11%5.41%5.80%6.01%8.14%12.49%13.14%32.85%19.21%17.77%15.97%
Interest Expense---01.19M03.40M3.83M4.30M2.38M1.35M291.87K231.14K
Interest Expense % of Total Revenue---0.00%0.05%0.00%0.12%0.11%0.12%0.14%0.05%0.01%0.01%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets832.55M1.20B1.81B2.60B3.74B4.69B6.03B9.51B10.85B10.61B11.72B12.04B12.63B
Total Liabilities99.33M164.18M325.41M348.06M408.00M424.18M555.88M569.09M686.02M1.02B972.52M988.45M998.57M
Total Equity733.17M1.04B1.49B2.26B3.34B4.27B5.47B8.94B10.17B9.59B10.74B11.05B11.63B
Cash232.05M245.50M112.49M535.03M817.31M593.53M483.22M2.82B3.31B2.89B2.44B902.78M2.09B
Total Debt4.03M19.95M81.43M34.61M27.08M35.86M38.37M9.09M20.12M15.89M5.45M3.31M-
Net Debt-228.02M-225.54M-31.06M-500.42M-790.23M-557.67M-444.84M-2.82B-3.29B-2.87B-2.44B-899.47M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow204.73M305.22M447.42M769.63M949.60M418.04M1.15B1.24B1.08B296.68M427.69M537.31M784.28M
Investing Cash Flow-63.25M-337.78M-680.06M-593.01M-726.00M-690.93M-1.18B-3.22B-498.13M-442.45M-1.30B-262.03M-
Financing Cash Flow-28.21M-1.78M59.53M-39.06M-31.43M2.24B3.68M2.24B-228.93M-100.87M754.70M-300.71M-
Capital Expenditure100.06M315.47M368.43M258.48M431.02M513.44M406.63M582.14M692.08M983.44M553.06M440.80M926.09M
Free Cash Flow104.66M-10.25M78.99M511.15M518.58M-95.40M747.30M659.20M386.09M-686.76M-443.61M96.51M-141.81M
Dividends Paid26.21M282.73K2.79M2.27M1.73M200.55M200.55M200.55M224.62M168.46M-420.55M597.53M
FCF to OCF51.12%-3.36%17.65%66.42%54.61%-22.82%64.76%53.10%35.81%-231.48%-103.72%17.96%-18.08%
Dividend Paid to FCF25.05%-2.76%3.53%0.44%0.33%-210.21%26.84%30.42%58.18%-24.53%-435.76%-421.34%

Earnings

Report DateAug 24, 2020Oct 27, 2020Apr 14, 2021Aug 26, 2021Oct 27, 2021Apr 27, 2022Aug 25, 2022Oct 27, 2022Mar 30, 2023Apr 27, 2023Apr 24, 2024Aug 28, 2024Oct 22, 2024Apr 24, 2025Aug 7, 2025Oct 30, 2025Dec 31, 2025Apr 22, 2026Aug 25, 2026
EPS Estimate----------0.230.350.240.330.520.510.450.450.77
EPS Actual0.330.700.340.330.890.20-0.55-0.38-0.04-0.050.160.350.350.530.490.360.550.550.70
Surprise-----------30.43%0.00%45.83%60.61%-5.77%-29.41%22.22%22.22%-9.09%
TimingAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hours-Pre-marketPre-market

Key Statistics & Ratios

Market Cap46.24B
Enterprise Value41.04B
Trailing P/E39.90
Forward P/E0.00
Price / Sales10.99
Price / Book3.80
EPS1.94
Book Value19.49
Revenue (TTM)4.21B
Gross Profit (TTM)3.13B
EBITDA1.21B
Profit Margin27.32%
Operating Margin31.87%
Return on Equity10.14%
Return on Assets4.42%
Shares Outstanding597.43M
Shares Float342.19M
Beta0.27
Dividend Yield1.29%
Dividend Rate1.00
Payout Ratio51.55%

Dividends

20221×
0.30Jun 20, 2022
20211×
0.40May 21, 2021
20201×
0.50Aug 20, 2020

Stock Splits

  • Aug 20, 20207:5